Literature DB >> 28689200

Optimal Medical Management Reduces Risk of Disease Progression and Ischemic Events in Asymptomatic Carotid Stenosis Patients: A Long-Term Follow-Up Study.

Zubair Shah1, Reza Masoomi, Rashmi Thapa, Mashhood Wani, John Chen, Buddhadeb Dawn, Marilyn Rymer, Kamal Gupta.   

Abstract

BACKGROUND AND
PURPOSE: To assess the effect of optimal medical management including atherosclerotic risk factor control on ischemic stroke (IS), transient ischemic attack (TIA), carotid revascularization (CRV), and progression of severity of carotid stenosis (PSCS) in patients with asymptomatic carotid artery stenosis (ACAS).
METHODS: We conducted a retrospective analysis of patients with ACAS (who had at least 3 serial carotid duplex ultrasounds) for incidence of IS, TIA, and PSCS.
RESULTS: Eight hundred sixty-four patients with a mean follow-up duration of 79 ± 36 months were included. IS/TIA and CRV occurred in 12.2% of the patients and PCSS was observed in 21.5% vessels. On univariate analysis it was found that low-density lipoprotein (LDL) levels >100 mg/dL, no statin or low-potency statins, average systolic blood pressure (SBP) ≥140 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg and history of smoking were predictors of the combined endpoint of IS/TIA/CRV and PSCS. On multivariate analysis, it was found that LDL >100 mg/dL, no statin or low-potency statin, SBP ≥140 mm Hg and/or DBP ≥90 mm Hg, and Hx of smoking were independent predictors of PSCS. Similarly no statin or low-potency statin, SBP ≥140 mm Hg and/or DBP ≥90 mm Hg, Hx of atrial fibrillation/flutter, Hx of chronic kidney disease, and PSCS were independent predictors of IS/TIA. No statin or low-potency statin, SBP ≥140 mm Hg and/or DBP ≥90 mm Hg, diabetes mellitus, baseline carotid artery stenosis ≥70%, and PSCS were found to be independent predictors of combined endpoint IS/TIA and CRV.
CONCLUSION: Intensive medical therapy in the patients with ACAS results in lower incidence of IS/TIA, CRV, and PSCS with a significant incremental beneficial effect.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Asymptomatic carotid stenosis; Ischemic stroke; Optimal medical management; Statins

Mesh:

Substances:

Year:  2017        PMID: 28689200     DOI: 10.1159/000477501

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  4 in total

1.  Atherosclerotic Extension of Carotid Arteries: An Insertion in Clinical Practice.

Authors:  M L Furlanetto; E F B Chagas; Payão Slm
Journal:  Int J Vasc Med       Date:  2020-06-23

2.  Treatment strategies for asymptomatic carotid artery stenosis in the era of lipid-lowering drugs: protocol for a systematic review and network meta-analysis.

Authors:  Xuesong Bai; Yao Feng; Long Li; Kun Yang; Tao Wang; Jichang Luo; Xue Wang; Feng Ling; Yan Ma; Liqun Jiao
Journal:  BMJ Open       Date:  2020-07-05       Impact factor: 2.692

3.  Management of carotid stenosis for primary and secondary prevention of stroke: state-of-the-art 2020: a critical review.

Authors:  Emmanuel Messas; Guillaume Goudot; Alison Halliday; Jonas Sitruk; Tristan Mirault; Lina Khider; Frederic Saldmann; Lucia Mazzolai; Victor Aboyans
Journal:  Eur Heart J Suppl       Date:  2020-12-06       Impact factor: 1.803

4.  The 2nd European Carotid Surgery Trial (ECST-2): rationale and protocol for a randomised clinical trial comparing immediate revascularisation versus optimised medical therapy alone in patients with symptomatic and asymptomatic carotid stenosis at low to intermediate risk of stroke.

Authors:  Paul J Nederkoorn; Martin M Brown; Leo H Bonati; Suk Fun Cheng; Twan J van Velzen; John Gregson; Toby Richards; Hans Rolf Jäger; Robert Simister; M Eline Kooi; Gert J de Borst; Francesca B Pizzini
Journal:  Trials       Date:  2022-07-27       Impact factor: 2.728

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.